logo
Plus   Neg
Share
Email

Moody's Sees Higher FY17 Results After Q4 Adj. EPS Miss Estimates - Quick Facts

Moody's Corp. (MCO) Friday said it expects fiscal 2017 earnings per share between $5.15 and $5.30 including the estimated $0.15 per share benefit resulting from the accounting standard update.

In the year 2016, the company reported earnings per share of $1.36, while adjusted earnings per share were $4.81.

On average, 14 analysts polled by Thomson Reuters expect earnings of $5.07 per share for the year. Analysts' estimates typically exclude special items.

Moody's expects full year 2017 revenue to increase in the mid-single-digit percent range. On a constant dollar basis, the revenue growth rate would be approximately 120 basis points higher.

Moody's projects an operating margin of approximately 43% and an adjusted operating margin of approximately 46%.

In its fourth quarter, Moody's recorded a net loss of $428.6 million, compared to net income of $217.9 million last year. Loss per share was $2.22, compared to earnings per share of $1.09 in the prior-year period. The latest results included a $3.63 loss from the settlement charge and an $0.18 gain from the non-cash foreign exchange benefit.

Adjusted net income was $237.3 million or $1.23 per share.

Moody's reported revenue of $942.1 million, up 9% from $865.9 million for the same period in 2015.

Analysts expected earnings of $1.24 per share on revenues of $908.13 million for the quarter.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT